– UK, Southampton – Synairgen plc (LON: SNG), the drug discovery, development, and commercialization company, today announced the appointment of Theodora Harold to its Board as an Independent Non-Executive Director and Chair of the Audit Committee with immediate effect.
“I am delighted to have Theodora joining the Board at this pivotal transition point for Synairgen. Her breadth and depth of experience brings a welcome new perspective to the Board and her expertise in the life sciences and biotech industries will be of great value to Synairgen particularly as we move into a new phase of rapid change with our Phase III trial for SNG001 (inhaled interferon beta) nearing completion.” said Board Chair, Simon Shaw.
About Theodora Harold
Theodora Harold has over 20 years of experience in the biotech sector and is currently CEO of Crescendo Biologics Ltd. She was previously part of the founding management teams of both PsiOxus Therapeutics Ltd and Mission Therapeutics Ltd. Theodora has previous non-executive director experience at Chronos Therapeutics Ltd.
Theodora is also a Chartered Accountant having qualified at PricewaterhouseCoopers.
Theodora Harold said: “Building on the ground-breaking work of Professor Sir Stephen Holgate and his team at the University of Southampton, Synairgen is at an important stage in its growth as it looks to expand access of this innovative inhaled interferon beta treatment to patients, particularly those severely ill with COVID-19. This is an exciting time to join the Synairgen team, and I look forward to working with Simon and the Board in pursuing a successful future for the Company.”
About Synairgen
Synairgen is a UK-based respiratory company focused on drug discovery, development, and commercialization. The Company’s primary focus is developing SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. Granted Fast Track status from the US Food and Drug Administration and deemed an Urgent Public Health study by the UK’s National Institute for Health Research, Synairgen’s Phase III clinical program is currently evaluating nebulized SNG001 in patients across 17 countries. In a Phase II trial in hospitalized COVID-19 patients, SNG001 demonstrated a greater than the twofold chance of recovery to ‘no limitation of activities’ versus placebo.
Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies, and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LON: SNG).
For more information: http://www.synairgen.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
